Cell Cycle Deregulation in Cancer

ISBN-13: 9781461425694 / Angielski / Miękka / 2012 / 206 str.

Greg H. Enders

Opis

Cancer is fundamentally a disease of abnormal cell proliferation: Cancer cells multiply when and where they should not. This proliferation entails escape from normal bounds imposed by the tissue environment, the internal biology of the cell (DNA damage, chromosomal imbalances, disorganized mitotic spindles), and the proliferative history of the cell (normal generational times). Some of the key oncogenic events in cancer directly perturb proteins that regulate progression through the cell division cycle, others alter cell cycle progression indirectly, through effects on signaling pathway that impinge on the cell cycle. This biology is fundamentally important in cancer therapy. Many of the workhorse treatments for cancer rely on killing proliferating cells. Furthermore, there is growing recognition that stem cell-transit amplifying cell hierarchies may persist or be generated during tumorigenesis, generating important functional heterogeneity in cell cycle control among tumor cells, with far-reaching scientific and clinical implications. This volume outlines major cell cycle perturbations that drive tumorigenesis and considers the prospects for using such knowledge in cancer therapy.

Spis treści

Starting the cell division cycle Elena Sotillo and Xavier Graña Escape from cellular quiescence Jun-Yuan Ji and Nicholas J. Dyson Interplay between Cyclin-dependent Kinases and E2F-dependent Transcription. A. Kathleen McClendon, Jeffry L. Dean, and Erik S. Knudsen Regulation of pre-RC assembly: A complex symphony orchestrated by CDKs Proliferation under duress Haomin Huang and Timothy J Yen Mitotic checkpoint and chromosome instability in cancer Jeremy P.H. Chow and Randy Y.C. Poon Mitotic catastrophe Robert D. Hontz and Maureen E. Murphy p53, ARF and the control of autophagy Long-term proliferation Andrea Viale and Pier Giuseppe Pelicci Regulation of self-renewing divisions in normal and leukaemia stem cells Eros Lazzerini Denchi Maintenance of Telomeres in Cancer Peter D. Adams The senescence secretome and its impact on tumor suppression and cancer Applications in preventing and treating cancer Pierre Lao-Sirieix and Rebecca C Fitzgerald Cell cycle deregulation in pre-neoplasia: case study of Barrett’s esophagus Neil Johnson and Geoffrey I. Shapiro Targeting cyclin dependent kinases for cancer therapy

Blurb

Modern studies of regulation of the cell division cycle were pioneered by Leland Hartwell, Paul Nurse, and Tim Hunt in yeast and marine invertebrates. This work identified proteins termed cyclins that fluxuate in abundance during progression through the cycle and partner with Cyclin dependent kinases (Cdks) to drive major cell cycle transitions. Much has been learned since about how these and other proteins control cell cycle progression in all eukaryotes, including man. Further research is uncovering how these controls are de-regulated in cancer, a disease of unbridled cell proliferation that is the leading cause of death in developed countries. However, there is much more to be learned, and the hard won gains are just beginning to impact cancer care. In 11 reviews by leading experts, this volume lays out the current state and directions of the field for biomedical scientists of all training levels.

The collection begins with three reviews that delineate how cells initiate the cell cycle, from growth factor stimulation to activation of key transcription programs and origins of DNA replication. The next three reviews address issues of proliferation under duress, including how derangement of mitotic checkpoints can lead to cell death or genetic instability and how recycling of intracellular molecules (autophagy) is regulated. The next three reviews address the special context of long-term proliferation—how it is regulated in stem cells, how it can erode telomeric structures on the tips of chromosomes, and how it can culminate in senescence. The last two reviews describe how cell cycle advances are beginning to touch patients, in the characterization of pre-malignant states and in cancer therapy.